Birth weight influences the initial response to growth hormone treatment in growth hormone-insufficient children

J C Achermann1, K Hamdani, P C Hindmarsh

  • 1London Centre for Paediatric Endocrinology, Middlesex Hospital, London, England.

Pediatrics
|August 1, 1998
PubMed

Insights

Birth weight impacts growth hormone (GH) treatment response in children with GH insufficiency. Lower birth weight standard deviation scores correlate with better initial height velocity response to GH therapy.

Area of Science:

  • Pediatric Endocrinology
  • Growth Hormone Therapy
  • Child Development

Background:

  • Isolated growth hormone (GH) insufficiency affects childhood growth.
  • Understanding factors influencing GH treatment response is crucial for optimizing outcomes.
  • Birth weight is a potential, yet understudied, determinant of GH therapy efficacy.

Purpose of the Study:

  • To investigate the relationship between birth weight and the initial response to GH replacement therapy in children with isolated GH insufficiency.
  • To identify birth weight as a predictor of height velocity changes during the first year of GH treatment.

Main Methods:

  • A longitudinal study involving 16 prepubertal children with isolated GH insufficiency.
  • Assessed height velocity standard deviation scores before and after GH treatment.
  • Utilized regression analysis to evaluate the influence of birth weight standard deviation score (BWSDS) and other variables on GH treatment response.

Main Results:

  • A positive correlation was observed between birth weight standard deviation score (BWSDS) and the change in height velocity standard deviation score (r = 0.64).
  • Higher BWSDS was associated with a greater increase in height velocity.
  • Stepwise linear regression confirmed BWSDS as a significant influencer of GH treatment response.

Conclusions:

  • Birth weight is a significant factor influencing the initial response to GH treatment in children with GH insufficiency.
  • This influence may suggest variations in the growth hormone or insulin-like growth factor axis sensitivity.
  • Further research is needed to determine the long-term effects on final height and optimal GH dosing strategies.
Abstract

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Physical Growth During Infancy and Toddlerhood01:18

Physical Growth During Infancy and Toddlerhood

Physical growth is especially rapid during the first three years of life, with the greatest rate in the first few months after birth. Although children continue to gain height and weight throughout infancy and toddlerhood, the rate of growth gradually slows during the second and third years. At most ages, boys are typically slightly taller and heavier than girls, reflecting a common pattern of early physical development.Changes in Body ProportionsAs infants become toddlers, their body...